5th International Conference on Lymphocyte Engineering
We are delighted to announce that CliniSciences is sponsoring the 5th International Conference on Lymphocyte Engineering that's taking place in ICLE, Munich, Germany, from February 20th to the 22nd, 2025.
The 5th edition of the groundbreaking ICLE Conferences series will bring together leading experts in lymphocyte engineering to push the boundaries of immune-gene and cell therapy. This event promises to be the ultimate platform for unveiling cutting-edge research, showcasing innovative clinical practices, and exploring the future of medical treatments.
This is your chance to be part of a transformative experience, where you'll contribute to shaping the future of healthcare breakthroughs. ICLE 2025 will spotlight the latest advancements in lymphocyte engineering and delve into how these breakthroughs are being integrated into real-world medicine.
ICLE 2025 will showcase the most recent scientific advancements in lymphocyte engineering and their real-world applications in medicine. Key topics include:
-
Real-World Experience, Novel Clinical Approaches, and Combination Therapies: Discover the potential synergy between engineered lymphocytes and other treatment modalities.
-
Superpowered Lymphocytes: Explore the engineering of lymphocytes for the co-expression of varied immune effectors alongside transgenic receptors.
-
Non-Viral CAR/TCR Gene Targeting: Learn about recent advancements in promoting integrations into lymphocyte genomes using nucleases or transposons.
-
CAR/TCR mRNA Therapies: Investigate the therapeutic effects of transient CAR/TCR expression through mRNA delivery.
-
Universal Donor Cells & Advanced TCR Engineering: Delve into allogeneic therapies, including those applying genome editing technologies.
-
Updated Clinical Data: Get a first look at post-marketing real-world data on approved T cell therapies.
-
Beyond Alpha-Beta T Cells: Discuss the engineering of alternative leukocytes, including Gamma-Delta T cells, iNKT cells, NK cells, B cells, and macrophages.
-
Targeting Non-Malignant Diseases: Explore applications in infectious diseases, autoimmune diseases, cardiovascular diseases, genetic disorders, and more.
-
In Vivo and Bedside T Cell Engineering: Examine advancements in scalable in vivo lymphocyte engineering, reducing costs, timelines, and pre-conditioning requirements.
We look forward to seeing you at the ICLE Conference 2025! For more details, visit the website